Kaynes Technology sinks 19% after Q4FY26 miss, targets cut

Sharp fall after March-quarter numbers

Shares of Kaynes Technology India Ltd fell nearly 20% on Thursday, coming close to the day’s circuit filter, after the company’s March 2026 quarter (Q4FY26) numbers disappointed the Street. The stock dropped 19.4% in early trade to ₹3,366 on BSE versus the previous close of ₹4,177.85. It later recovered a bit, but remained sharply lower. At 9:42 AM, the stock was down 16.9% at ₹3,470.95.

The move added to a prolonged correction in the counter. Kaynes Technology is down more than 56% from its 52-week high of ₹7,705 hit in October 2025. The day’s decline also came amid heightened focus on disclosures, working-capital intensity, and cash-flow trends that have featured repeatedly in recent brokerage notes.

What brokerages flagged in Q4FY26

Nuvama Institutional Equities described Kaynes’ Q4 as largely weaker than expected, with revenue and EBITDA growth of 26% and 15% year-on-year, respectively, but still missing estimates. It also said adjusted PAT declined 21% year-on-year. The brokerage highlighted operating cash flow (OCF) of negative ₹600 crore, against guidance of “marginally negative to positive”.

A key driver, per the note, was working-capital stretch. Nuvama said working-capital days rose from 87 to 125. It also pointed to a challenging near-term set-up, prompting earnings downgrades.

Target cuts and downgrades: Nuvama and JPMorgan

Following the Q4 performance and the near-term outlook, Nuvama said it cut FY27E and FY28E EPS by 22% and 20%. It valued the company at 35 times FY29 EPS, applying an 18% discount, and arrived at a March 2027 target price of ₹3,550, lowered from ₹5,500 earlier. Nuvama also downgraded the stock to a ‘hold’ and said the target price was reduced by 35%.

JP Morgan also turned more cautious. The overseas brokerage downgraded Kaynes Technology to ‘neutral’ from ‘overweight’ and reduced its target price to ₹4,000 from ₹6,000 earlier, a cut of more than 33%. JPMorgan said it cut earnings estimates by 12% to 17% over the next two years, led by reductions across the core EMS business and the OSAT business.

CLSA stays positive, but calls out balance-sheet monitorables

CLSA said it was expecting a negative stock reaction after the results and after a further deterioration in the balance sheet, which it described as a key monitorable. Even so, the brokerage maintained an ‘outperform’ rating with a target price of ₹4,200.

This split in stance reflects a market that is debating near-term execution and cash-flow pressure versus longer-term growth plans.

Disclosures and accounting concerns remain in focus

The selling has also been linked to concerns raised in brokerage reports around accounting and disclosures. Kotak Institutional Equities flagged discrepancies in inter-company transaction disclosures between the parent and subsidiaries. The brokerage noted significant unrecorded transactions and receivables, and also raised concerns about accounting for goodwill and intangibles.

In another regulatory-related development referenced in market coverage, a SEBI disclosure dated March 10, 2025 pointed to concerns over maintenance of a Structured Digital Database (SDD) for financial results for the period ending March 31, 2023, tied to insider trading allegations involving the managing director.

Volatility in the stock: rebounds amid drawdowns

Kaynes Technology has seen sharp two-way moves. One market update noted the stock rebounded 14% on Tuesday after a 30% drop in four days, with the sell-off linked to a Kotak report flagging disclosure gaps, while the company said issues were resolved.

Separately, Elara Capital was cited as taking the view that recent concerns around accounting and cash flows were overstated and did not alter the company’s long-term growth outlook. Still, Thursday’s slide shows the market is reacting strongly to earnings delivery and cash-flow signals.

Key numbers investors are tracking

The immediate focus has shifted to profitability, cash generation, and working-capital discipline. Alongside the Q4 OCF figure of negative ₹600 crore cited by Nuvama, another report noted operating cash outflow of ₹80 crore in FY25 and a further outflow of ₹220 crore in the first half of the current financial year.

Costs were also in focus. Market coverage of the Q4 result pointed to higher material, employee and finance costs weighing on profitability.

Snapshot table: price action and brokerage targets

Broader context: guidance, OSAT capex, and order visibility

The stock has previously reacted to guidance changes. One earlier episode noted Kaynes slumped 19% after management slashed FY25 revenue guidance post Q3 results. Another market timeline referenced an announcement in March 2026 of an OSAT (chip packaging) facility with capex of ₹1,400 crore.

Operational momentum has also been uneven across quarters in the coverage cited. A separate data point referenced Q3 FY26 revenue of ₹693 crore, and another report highlighted defence order inflows of ₹820 crore with execution timelines of 24 to 36 months. An order book figure of ₹8,099.4 crore was also cited in market commentary around the company’s growth visibility.

Market impact: what the sell-off is signalling

Thursday’s fall was driven by a mix of earnings disappointment, cash-flow pressure, and the market’s sensitivity to disclosure-related questions. Target cuts and rating changes add to near-term uncertainty for investors who track consensus. One report cited brokerage recommendation distribution as: seven ‘buy’, two ‘hold’, and one ‘sell’, with an average target price of ₹6,639.

For the sector, the episode underlines how EMS businesses can see sharp valuation and sentiment swings when working capital expands and cash conversion weakens, even if revenue growth remains healthy.

Why this matters: the monitorables are now clearer

The key monitorables flagged across notes are consistent: working capital, operating cash flow, and clarity on accounting and related-party disclosures. Nuvama’s jump in working-capital days (87 to 125) and the negative OCF number (negative ₹600 crore) frame the near-term debate.

At the same time, the range of targets and ratings shows investors are still weighing long-term optionality, including OSAT, against near-term execution risks and cost pressures.

Conclusion

Kaynes Technology’s near-20% drop reflects a market that is repricing the stock after a weaker-than-expected Q4FY26, negative operating cash flow, and renewed scrutiny on working capital and disclosures. With brokerages divided from ‘reduce/neutral’ to ‘outperform/buy’, the next set of monitorables will be updates on cash-flow improvement, working-capital discipline, and clarity around disclosures in upcoming filings and management commentary.